A New Therapeutic Target in Non–Small Cell Lung Cancer: HER2
This article summarizes key data presented during a virtual OncLive® Scientific Interchange & Workshop in which oncologists who specialize in lung cancer treatment discussed their practices for HER2 testing and the potential role of emerging antibody-drug conjugates and novel HER2-targeted small-molecule tyrosine kinase inhibitors for treatment of HER2-altered NSCLC.
EP: 1.Dr. Iams on Emerging TKIs and ADCs in HER2-Mutant Lung Cancer
EP: 2.Dr. Bazhenova on the Importance of Testing for HER2 Mutations in Lung Cancer
EP: 3.Dr. Porter on Potential Sequencing With ADCs and TKIs in HER2+ Lung Cancer
Now Viewing
EP: 4.A New Therapeutic Target in Non–Small Cell Lung Cancer: HER2
Related Videos
Related Content
